Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 1,520 Shares of Stock

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 1,520 shares of the firm’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Glaukos Trading Up 0.5 %

GKOS traded up $0.54 during trading on Thursday, hitting $103.67. The company’s stock had a trading volume of 426,365 shares, compared to its average volume of 585,418. The firm has a market capitalization of $5.86 billion, a P/E ratio of -36.12 and a beta of 0.99. Glaukos Co. has a twelve month low of $88.16 and a twelve month high of $163.71. The stock’s fifty day moving average price is $131.61 and its 200-day moving average price is $135.83. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Analysts anticipate that Glaukos Co. will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Glaukos

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its stake in Glaukos by 47.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock worth $83,609,000 after buying an additional 207,338 shares during the period. Algert Global LLC raised its position in shares of Glaukos by 162.4% during the third quarter. Algert Global LLC now owns 13,260 shares of the medical instruments supplier’s stock worth $1,728,000 after purchasing an additional 8,206 shares during the period. Harvest Fund Management Co. Ltd lifted its holdings in shares of Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 860 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Glaukos by 2.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 28,343 shares of the medical instruments supplier’s stock valued at $3,693,000 after purchasing an additional 632 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in Glaukos by 186.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier’s stock valued at $1,788,000 after purchasing an additional 8,942 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on GKOS shares. Wells Fargo & Company boosted their price target on Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Mizuho raised shares of Glaukos from a “neutral” rating to an “outperform” rating and raised their price target for the company from $140.00 to $200.00 in a research note on Wednesday, February 19th. Stifel Nicolaus raised their target price on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, December 31st. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price target (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Finally, Truist Financial raised their price objective on Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.